Hi All, I’m not sure how old this is but what got me was the statement “Apricitabine received fast-track approval status from the FDA”
It’s a good read anyway
Apricitabine, previously known as AVX754 and SPD754, is a nucleoside reverse transcriptase inhibitor (NRTI). Apricitabine is the negative enantiomer of a member of the 4-thio heterosubstituted nucleoside analogue class. It is a novel cytidine analogue with activity against HIV strains that are resistant to other NRTIs. Apricitabine is a deoxycytidine analogue entering Phase IIb studies for the treatment of HIV infection. It is being studied as a first choice, second regimen drug for the treatment of HIV infection in people who have failed treatment with lamivudine. Apricitabine received fast-track approval status from the FDA.
This is the link to the whole story! http://aidsinfo.nih.gov/DrugsNew/DrugDetailT.aspx?int_id=415
A
AVX Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
